The post 3 cheap stocks that could turn $1,000 into $10,000 appeared on BitcoinEthereumNews.com. At the start of 2025, the stock market appeared unstable as mostThe post 3 cheap stocks that could turn $1,000 into $10,000 appeared on BitcoinEthereumNews.com. At the start of 2025, the stock market appeared unstable as most

3 cheap stocks that could turn $1,000 into $10,000

At the start of 2025, the stock market appeared unstable as most major assets were, seemingly, very overvalued. Despite this, there was no shortage of opportunities for savvy investors to find undervalued, cheap stocks that enabled them to turn a $1,000 into $10,000 of profit.

The start of 2026 appears similar, and though some fear – as they have for a long time – that the artificial intelligence (AI) boom is a bubble about to burst, the S&P 500 stock market index has, on multiple days in January, closed at unprecedented highs.

With both the dangers and opportunities in mind, Finbold decided to examine potentially undervalued stocks that could help investors turn relatively modest investments into hefty returns in the mid to long-term.

Rocket Pharmaceuticals (NASDAQ: RCKT)

Rocket Pharmaceuticals (NASDAQ: RCKT) represents one of the binaries frequently found among cheap stocks of very ambitious companies. In a nutshell, the firm is a clinical-stage gene therapy developer examining rare diseases.

RCKT shares are also, by any standard, very cheap in January 2026 due to a trial-related calamity in early 2025 that sent them plunging from approximately $6.59 to about $2.50 and, eventually, to their press time price of $3.80.

RCKT stock YTD price chart. Source: Google

Rocket’s latest stock market trend has, however, been mildly positive with an 8% year-to-date (YTD) rally, and the company has continued working on novel treatments such as adeno-associated viral (AAV) and lentiviral (LV) gene therapy programs, with the project targeting the Danon disease being especially noteworthy, considering it is in Phase 2 trials.

Simultaneously, while there is no doubt that a Rocket Pharmaceuticals investment is only for the risk-seekers, the potential payouts should the company succeed are staggering. 

In fact, the potential upside is so significant that the average Wall Street 12-month price target for the company, per the data Finbold retrieved from TipRanks on January 14, stands at $8.63 – indicating a 127% upside is anticipated before the end of 2026.

Average analyst 12-month price target for RCKT stock. Source: TipRanks

Fiserv (NASDAQ: FISV)

Unlike Rocket, Fiserv (NASDAQ: FISV) is a well-established firm that is deeply integrated into the global payments and financial infrastructure. 

A disastrous earnings miss in late 2025 led to a staggering 40% single-day drop and, more importantly for investors in January 2026, to FISV stock becoming significantly undervalued at press time with a price of just $66.79.

FISV stock six-month price chart. Source: CNBC

Indeed, Fiserv shares could be an example of a value trap turned value play, as many analysts estimated they are significantly undervalued against the company’s fundamentals, and there is a trend toward digital payments and banking technology companies growing.

Furthermore, despite the overall stock ratings still being cautious, it is noteworthy that Wall Street anticipates, on average, that FISV stock will rally at least some 40% in 2026.

Lastly, while Congressional trading patterns are hardly a common indicator, Fiserv also has a roundabout endorsement in the form of Representative Gilbert Cisneros purchasing its shares in December. Cisneros recently drew public attention for seeing a 54% return in a month on a war stock investment he had made late in 2025.

Intel (NASDAQ: INTC)

Though Intel (NASDAQ: INTC) has been gaining ground through 2025, the semiconductor giant remains – with its press time stock price of $47.29 – significantly cheaper than both Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD).

INTC stock 5-year price chart. Source: Google

Simultaneously, despite its woes in recent years, the firm is both well-established and strategically important for the United States, making its continued survival all but guaranteed, and renewed thriving rather likely.

The bull case for INTC shares has also become even stronger in January as its recent growth has set it on a path to overtaking the Korean giant Samsung as the world’s second-largest microchip foundry. 

Such a development would simultaneously emphasize Intel’s national importance, as the global semiconductor production is perpetually at risk due to being concentrated on the politically-sensitive island of Taiwan via the Taiwan Semiconductor Manufacturing Company (NYSE: TSM).

Featured image via Shutterstock

Source: https://finbold.com/3-cheap-stocks-that-could-turn-1000-into-10000/

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.13406
$0.13406$0.13406
+5.80%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Ethereum Price Prediction: ETH Targets $10,000 In 2026 But Layer Brett Could Reach $1 From $0.0058

Ethereum Price Prediction: ETH Targets $10,000 In 2026 But Layer Brett Could Reach $1 From $0.0058

Ethereum price predictions are turning heads, with analysts suggesting ETH could climb to $10,000 by 2026 as institutional demand and network upgrades drive growth. While Ethereum remains a blue-chip asset, investors looking for sharper multiples are eyeing Layer Brett (LBRETT). Currently in presale at just $0.0058, the Ethereum Layer 2 meme coin is drawing huge [...] The post Ethereum Price Prediction: ETH Targets $10,000 In 2026 But Layer Brett Could Reach $1 From $0.0058 appeared first on Blockonomi.
Share
Blockonomi2025/09/17 23:45
‘Primal’ Creator Genndy Tartakovsky Talks Zombified Season 3

‘Primal’ Creator Genndy Tartakovsky Talks Zombified Season 3

The post ‘Primal’ Creator Genndy Tartakovsky Talks Zombified Season 3 appeared on BitcoinEthereumNews.com. A zombified Spear appears in Season 3 of Adult Swim’s
Share
BitcoinEthereumNews2026/01/15 06:04
‘Dr. Quinn’ Co-Stars Jane Seymour And Joe Lando Reuniting In New Season Of ‘Harry Wild’

‘Dr. Quinn’ Co-Stars Jane Seymour And Joe Lando Reuniting In New Season Of ‘Harry Wild’

The post ‘Dr. Quinn’ Co-Stars Jane Seymour And Joe Lando Reuniting In New Season Of ‘Harry Wild’ appeared on BitcoinEthereumNews.com. Joe Lando and Janey Seymour in “Harry Wild.” Courtesy: AMC / Acorn Jane Seymour is getting her favorite frontier friend to join her in her latest series. In the mid-90s Seymour spent six seasons as Dr. Micheala Quinn on Dr. Quinn, Medicine Woman. During the run of the series, Dr. Quinn met, married, and started a family with local frontiersman Byron Sully, also known simply as Sully, played by Joe Lando. Now, the duo will once again be partnering up, but this time to solve crimes in Seymour’s latest show, Harry Wild. In the series, literature professor Harriet ‘Harry’ Wild found herself at crossroads, having difficulty adjusting to retirement. After a stint staying with her police detective son, Charlie, Harry begins to investigate crimes herself, now finding an unlikely new sleuthing partner, a teen who had mugged Harry. In the upcoming fifth season, now in production in Dublin, Ireland, Lando will join the cast, playing Pierce Kennedy, the new State Pathologist, who becomes a charming and handsome natural ally for Harry. Promotional portrait of British actress Jane Seymour (born Joyce Penelope Wilhelmina Frankenberg), as Dr. Michaela ‘Mike’ Quinn, and American actor Joe Lando, as Byron Sully, as they pose with horses for the made-for-tv movie ‘Dr. Quinn, Medicine Woman: the Movie,’ 1999. (Photo by Spike Nannarello/CBS Photo Archive/Getty Images) Getty Images Emmy-Award Winner Seymour also serves as executive producer on the series. The new season finds Harry and Fergus delving into the worlds of whiskey-making, theatre and musical-tattoos, chasing a gang of middle-aged lady burglars and working to deal with a murder close to home. Debuting in 2026, Harry Wild Season 5 will consist of six episodes. Ahead of the new season, a 2-part Harry Wild Special will debut exclusively on Acorn TV on Monday, November 24th. Source: https://www.forbes.com/sites/anneeaston/2025/09/17/dr-quinn-co-stars-jane-seymour-and-joe-lando-reuniting-in-new-season-of-harry-wild/
Share
BitcoinEthereumNews2025/09/18 07:05